BioCentury on BioBusiness,
Tools & Techniques
CAT and mouse
Monday, February 12, 2007
AstraZeneca plc has taken another step toward fulfilling its ambition to have biologics represent 25% of its Phase III programs by 2010. Last week, the company licensed Regeneron Pharmaceuticals Inc.’s VelocImmune technology, a mouse-based production platform for human monoclonal antibodies that should complement the phage and ribosome display platforms the pharma company got from its acquisition of Cambridge Antibody Technology last year.
Using transgenic mice to develop human MAbs is hardly new. Indeed, AstraZeneca (LSE:AZN; AZN, London, U.K.) is continuing its collaboration on XenoMouse-derived human MAbs with Amgen Inc. (AMGN, Thousand Oaks, Calif.), which inherited the technology when it acquired Abgenix Inc.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]